A citation-based method for searching scientific literature

David A Schaer, Richard P Beckmann, Jack A Dempsey, Lysiane Huber, Amelie Forest, Nelusha Amaladas, Yanxia Li, Ying Cindy Wang, Erik R Rasmussen, Darin Chin, Andrew Capen, Carmine Carpenito, Kirk A Staschke, Linda A Chung, Lacey M Litchfield, Farhana F Merzoug, Xueqian Gong, Philip W Iversen, Sean Buchanan, Alfonso de Dios, Ruslan D Novosiadly, Michael Kalos. Cell Rep 2018
Times Cited: 154







List of co-cited articles
1091 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


CDK4/6 inhibition triggers anti-tumour immunity.
Shom Goel, Molly J DeCristo, April C Watt, Haley BrinJones, Jaclyn Sceneay, Ben B Li, Naveed Khan, Jessalyn M Ubellacker, Shaozhen Xie, Otto Metzger-Filho,[...]. Nature 2017
498
81

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Jiehui Deng, Eric S Wang, Russell W Jenkins, Shuai Li, Ruben Dries, Kathleen Yates, Sandeep Chhabra, Wei Huang, Hongye Liu, Amir R Aref,[...]. Cancer Discov 2018
225
55

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Jinfang Zhang, Xia Bu, Haizhen Wang, Yasheng Zhu, Yan Geng, Naoe Taira Nihira, Yuyong Tan, Yanpeng Ci, Fei Wu, Xiangpeng Dai,[...]. Nature 2018
308
40

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A Kaufman,[...]. J Clin Oncol 2017
576
22

Palbociclib and Letrozole in Advanced Breast Cancer.
Richard S Finn, Miguel Martin, Hope S Rugo, Stephen Jones, Seock-Ah Im, Karen Gelmon, Nadia Harbeck, Oleg N Lipatov, Janice M Walshe, Stacy Moulder,[...]. N Engl J Med 2016
21

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
20

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Nicholas C Turner, Dennis J Slamon, Jungsil Ro, Igor Bondarenko, Seock-Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma,[...]. N Engl J Med 2018
342
18

Treating cancer with selective CDK4/6 inhibitors.
Ben O'Leary, Richard S Finn, Nicholas C Turner. Nat Rev Clin Oncol 2016
463
17

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Livnat Jerby-Arnon, Parin Shah, Michael S Cuoco, Christopher Rodman, Mei-Ju Su, Johannes C Melms, Rachel Leeson, Abhay Kanodia, Shaolin Mei, Jia-Ren Lin,[...]. Cell 2018
323
17

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
Maura N Dickler, Sara M Tolaney, Hope S Rugo, Javier Cortés, Véronique Diéras, Debra Patt, Hans Wildiers, Clifford A Hudis, Joyce O'Shaughnessy, Esther Zamora,[...]. Clin Cancer Res 2017
261
17

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Matthew P Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch-Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin-Cheh Chen, Luis Manso,[...]. J Clin Oncol 2017
535
17

Targeting CDK4 and CDK6: From Discovery to Therapy.
Charles J Sherr, David Beach, Geoffrey I Shapiro. Cancer Discov 2016
444
17

The history and future of targeting cyclin-dependent kinases in cancer therapy.
Uzma Asghar, Agnieszka K Witkiewicz, Nicholas C Turner, Erik S Knudsen. Nat Rev Drug Discov 2015
782
17

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Maria Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Martín A Rivas, Rosalind J Cutts, Isaac Garcia-Murillas, Alex Pearson, Marta Guzman, Olga Rodriguez, Judit Grueso,[...]. Cancer Res 2016
292
15

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen, Amrita J Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst,[...]. Breast Cancer Res 2009
812
15

Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
Zhi Ling Teo, Stephanie Versaci, Sathana Dushyanthen, Franco Caramia, Peter Savas, Chris P Mintoff, Magnus Zethoven, Balaji Virassamy, Stephen J Luen, Grant A McArthur,[...]. Cancer Res 2017
75
20

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.
Smruthi Vijayaraghavan, Cansu Karakas, Iman Doostan, Xian Chen, Tuyen Bui, Min Yi, Akshara S Raghavendra, Yang Zhao, Sami I Bashour, Nuhad K Ibrahim,[...]. Nat Commun 2017
124
15

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Amita Patnaik, Lee S Rosen, Sara M Tolaney, Anthony W Tolcher, Jonathan W Goldman, Leena Gandhi, Kyriakos P Papadopoulos, Muralidhar Beeram, Drew W Rasco, John F Hilton,[...]. Cancer Discov 2016
336
14

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
Mary E Klein, Marta Kovatcheva, Lara E Davis, William D Tap, Andrew Koff. Cancer Cell 2018
120
14

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe S Sonke, Shani Paluch-Shimon, Mario Campone, Kimberly L Blackwell, Fabrice André, Eric P Winer,[...]. N Engl J Med 2016
794
14

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Lawrence M Gelbert, Shufen Cai, Xi Lin, Concepcion Sanchez-Martinez, Miriam Del Prado, Maria Jose Lallena, Raquel Torres, Rose T Ajamie, Graham N Wishart, Robert Steven Flack,[...]. Invest New Drugs 2014
270
13

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
Shom Goel, Qi Wang, April C Watt, Sara M Tolaney, Deborah A Dillon, Wei Li, Susanne Ramm, Adam C Palmer, Haluk Yuzugullu, Vinay Varadan,[...]. Cancer Cell 2016
203
13

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Richard S Finn, John P Crown, Istvan Lang, Katalin Boer, Igor M Bondarenko, Sergey O Kulyk, Johannes Ettl, Ravindranath Patel, Tamas Pinter, Marcus Schmidt,[...]. Lancet Oncol 2015
12

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Dennis J Slamon, Patrick Neven, Stephen Chia, Peter A Fasching, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia Val Bianchi, Francisco J Esteva, Miguel Martín,[...]. J Clin Oncol 2018
327
12


The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Haizhen Wang, Brandon N Nicolay, Joel M Chick, Xueliang Gao, Yan Geng, Hong Ren, Hui Gao, Guizhi Yang, Juliet A Williams, Jan M Suski,[...]. Nature 2017
160
12

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Zhiqiang Li, Pedram Razavi, Qing Li, Weiyi Toy, Bo Liu, Christina Ping, Wilson Hsieh, Francisco Sanchez-Vega, David N Brown, Arnaud F Da Cruz Paula,[...]. Cancer Cell 2018
128
12



Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, S Chandarlapaty. Oncogene 2017
147
11

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
Xin Jin, Donglin Ding, Yuqian Yan, Hui Li, Bo Wang, Linlin Ma, Zhenqing Ye, Tao Ma, Qiang Wu, Daniel N Rodrigues,[...]. Mol Cell 2019
74
14

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.
Jorge Franco, Uthra Balaji, Elizaveta Freinkman, Agnieszka K Witkiewicz, Erik S Knudsen. Cell Rep 2016
100
11

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Xueqian Gong, Lacey M Litchfield, Yue Webster, Li-Chun Chio, Swee Seong Wong, Trent R Stewart, Michele Dowless, Jack Dempsey, Yi Zeng, Raquel Torres,[...]. Cancer Cell 2017
88
12

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Cynthia X Ma, Feng Gao, Jingqin Luo, Donald W Northfelt, Matthew Goetz, Andres Forero, Jeremy Hoog, Michael Naughton, Foluso Ademuyiwa, Rama Suresh,[...]. Clin Cancer Res 2017
149
10

Cell cycle, CDKs and cancer: a changing paradigm.
Marcos Malumbres, Mariano Barbacid. Nat Rev Cancer 2009
10

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Debu Tripathy, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Nadia Harbeck, Sara A Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee,[...]. Lancet Oncol 2018
293
10

NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
Marcus Ruscetti, Josef Leibold, Matthew J Bott, Myles Fennell, Amanda Kulick, Nelson R Salgado, Chi-Chao Chen, Yu-Jui Ho, Francisco J Sanchez-Rivera, Judith Feucht,[...]. Science 2018
104
10

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
David W Fry, Patricia J Harvey, Paul R Keller, William L Elliott, Maryanne Meade, Erin Trachet, Mudher Albassam, XianXian Zheng, Wilbur R Leopold, Nancy K Pryer,[...]. Mol Cancer Ther 2004
779
10

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
Seock-Ah Im, Yen-Shen Lu, Aditya Bardia, Nadia Harbeck, Marco Colleoni, Fabio Franke, Louis Chow, Joohyuk Sohn, Keun-Seok Lee, Saul Campos-Gomez,[...]. N Engl J Med 2019
273
10

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
Sara A Hurvitz, Miguel Martin, Michael F Press, David Chan, María Fernandez-Abad, Edgar Petru, Regan Rostorfer, Valentina Guarneri, Chiun-Sheng Huang, Susana Barriga,[...]. Clin Cancer Res 2020
43
23

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
Kamal Pandey, Hee-Jung An, Seung Ki Kim, Seung Ah Lee, Sewha Kim, Sun Min Lim, Gun Min Kim, Joohyuk Sohn, Yong Wha Moon. Int J Cancer 2019
86
10


MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
Peter J R Ebert, Jeanne Cheung, Yagai Yang, Erin McNamara, Rebecca Hong, Marina Moskalenko, Stephen E Gould, Heather Maecker, Bryan A Irving, Jeong M Kim,[...]. Immunity 2016
348
9

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.
Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, Carmen Baquero, Beatriz Alvarez, Joaquín Amat, Ann M McNulty, Xueqian Gong, Karsten Boehnke, Jian Du,[...]. Oncotarget 2017
60
15

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Nicholas C Turner, Yuan Liu, Zhou Zhu, Sherene Loi, Marco Colleoni, Sibylle Loibl, Angela DeMichele, Nadia Harbeck, Fabrice André, Mohamed Amine Bayar,[...]. J Clin Oncol 2019
107
9

Cell cycle proteins as promising targets in cancer therapy.
Tobias Otto, Piotr Sicinski. Nat Rev Cancer 2017
679
9

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
Ben O'Leary, Rosalind J Cutts, Yuan Liu, Sarah Hrebien, Xin Huang, Kerry Fenwick, Fabrice André, Sibylle Loibl, Sherene Loi, Isaac Garcia-Murillas,[...]. Cancer Discov 2018
167
9

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
R Condorelli, L Spring, J O'Shaughnessy, L Lacroix, C Bailleux, V Scott, J Dubois, R J Nagy, R B Lanman, A J Iafrate,[...]. Ann Oncol 2018
138
9

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, Gabor Rubovszky, Mario Campone, Sibylle Loibl, Hope S Rugo, Hiroji Iwata, Pierfranco Conte, Ingrid A Mayer, Bella Kaufman,[...]. N Engl J Med 2019
616
9

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee,[...]. Clin Cancer Res 2017
368
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.